Scynexis Advances SCY-770 into Phase 2 for ADPKD After Favorable…

Event summary

SCY-770 demonstrated favorable safety and tolerability in Phase 1 study across 25 healthy participants.
Phase 2 proof-of-concept study in ADPKD patients remains on track to initiate in Q4 2026.
SCY-770 is a first-in-class, selective oral direct AMPK activator targeting multiple ADPKD drivers.
SCY-770 has been granted Orphan Drug Designation by the FDA for ADPKD treatment.

The big picture

Scynexis' advancement of SCY-770 into Phase 2 reflects the growing focus on novel, disease-modifying therapies for ADPKD, a condition with significant unmet medical need. The Phase 1 results position SCY-770 as a potential first-in-class treatment, competing with Jynarque, which despite its $1.5 billion in U.S. sales faces limitations in patient uptake due to safety and tolerability concerns. The success of SCY-770 could expand treatment options for the 140,000 U.S. patients living with ADPKD.

What we're watching

Clinical Progress: Whether SCY-770 can demonstrate efficacy in Phase 2, potentially positioning it as a differentiated therapy for ADPKD.
Regulatory Pathway: The pace at which the FDA aligns with Scynexis on the Phase 2 study design and potential expedited development pathways.
Market Differentiation: How SCY-770's multi-mechanistic approach compares to existing ADPKD treatments like Jynarque, particularly in safety and tolerability.